CervoMed Q3 net loss widens

Reuters

Nov 10

<a href="https://laohu8.com/S/CRVO">CervoMed</a> Q3 net loss widens

Overview

CervoMed Q3 2025 net loss of $7.7 mln misses analyst expectations
Cash position decreased to $27.3 mln as of September 30, 2025

Outlook

CervoMed plans to initiate a global pivotal Phase 3 trial in DLB in H2 2026
Company expects initial biomarker data from Phase 2a FTD trial in 2026
CervoMed aligned with FDA on Phase 3 trial design for neflamapimod in DLB

Result Drivers

CASH POSITION - As of September 30, CervoMed had 27.3 mln in cash, cash equivalents, and marketable securities vs $38.9 mln as of December 31
OPERATING PLAN - CervoMed believes its cash will fund operations into Q3 2026

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income	Miss	-$7.70 mln	-$6.33 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CervoMed Inc is $20.00, about 65.4% above its November 7 closing price of $6.92

Press Release: ID:nGNX3MgWQc

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582587308"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582587308\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582587308?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582587308","market":"nz","top_or_hot":-1,"title":"CervoMed Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>CervoMed Q3 2025 net loss of $7.7 mln misses analyst expectations</p></li><li><p>Cash position decreased to $27.3 mln as of September 30, 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>CervoMed plans to initiate a global pivotal Phase 3 trial in DLB in H2 2026</p></li><li><p>Company expects initial biomarker data from Phase 2a FTD trial in 2026</p></li><li><p>CervoMed aligned with FDA on Phase 3 trial design for neflamapimod in DLB</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CASH POSITION - As of September 30, CervoMed had 27.3 mln in cash, cash equivalents, and marketable securities vs $38.9 mln as of December 31</p></li><li><p>OPERATING PLAN - CervoMed believes its cash will fund operations into Q3 2026</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$7.70 mln</p></td><td><p>-$6.33 mln (5 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for CervoMed Inc is $20.00, about 65.4% above its November 7 closing price of $6.92</p></li></ul><p>Press Release: <span>ID:nGNX3MgWQc</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CervoMed Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCervoMed Q3 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>CervoMed Q3 2025 net loss of $7.7 mln misses analyst expectations</p></li><li><p>Cash position decreased to $27.3 mln as of September 30, 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>CervoMed plans to initiate a global pivotal Phase 3 trial in DLB in H2 2026</p></li><li><p>Company expects initial biomarker data from Phase 2a FTD trial in 2026</p></li><li><p>CervoMed aligned with FDA on Phase 3 trial design for neflamapimod in DLB</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CASH POSITION - As of September 30, CervoMed had 27.3 mln in cash, cash equivalents, and marketable securities vs $38.9 mln as of December 31</p></li><li><p>OPERATING PLAN - CervoMed believes its cash will fund operations into Q3 2026</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$7.70 mln</p></td><td><p>-$6.33 mln (5 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for CervoMed Inc is $20.00, about 65.4% above its November 7 closing price of $6.92</p></li></ul><p>Press Release: <span>ID:nGNX3MgWQc</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVO","symbol_name":"CervoMed","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0DA:1","article_id":"2582587308","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582587308","pubTimestamp":1762776576,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CervoMed Q3 net loss widensOverviewCervoMed Q3 2025 net loss of $7.7 mln misses analyst expectationsCash position decreased to $27.3 mln as of September 30, 2025OutlookCervoMed plans to initiate a glo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVO":"CervoMed","BK4139":"生物科技"},"translate_title":"CervoMed第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":0.9},"content_text":"CervoMed Q3 net loss widensOverviewCervoMed Q3 2025 net loss of $7.7 mln misses analyst expectationsCash position decreased to $27.3 mln as of September 30, 2025OutlookCervoMed plans to initiate a global pivotal Phase 3 trial in DLB in H2 2026Company expects initial biomarker data from Phase 2a FTD trial in 2026CervoMed aligned with FDA on Phase 3 trial design for neflamapimod in DLBResult DriversCASH POSITION - As of September 30, CervoMed had 27.3 mln in cash, cash equivalents, and marketable securities vs $38.9 mln as of December 31OPERATING PLAN - CervoMed believes its cash will fund operations into Q3 2026Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net IncomeMiss-$7.70 mln-$6.33 mln (5 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for CervoMed Inc is $20.00, about 65.4% above its November 7 closing price of $6.92Press Release: ID:nGNX3MgWQcFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}